ATNM FINANCIAL STATEMENTS

Actinium Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

ATNMActinium Pharmaceuticals Inc

🇺🇸 USA · AMEX · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue90 K $-88.9%

Gross Profit281 K $—

Operating Income-25.5 M $—

EBITDA-22.6 M $—

Net Income-23.5 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
ATNM	-88.9%	312.2%	-25,150.0%	-26,078.9%
RTALB	24.0%	35.1%	9.0%	136.3%
MSB	410.4%	-32.0%	-76.6%	-115.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
ATNM	-88.9%	312.2%	-25,150.0%	-26,078.9%
SGMO	-45.8%	100.0%	-339.9%	-356.9%
OTLK	-2.1%	-360.9%	-18,634.1%	-18,297.5%
PDSB	-100.0%	—	—	—
PMVP	—	—	—	—
VRCA	417.6%	89.5%	-30.6%	-48.0%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity2.3 M $5%
Current Liabilities7.3 M $16%
Long-term Liabilities35.8 M $79%

Key Figures

YoY change

Total Assets45.4 M $-33.8%

Total Liabilities43.1 M $+0.4%

Total Equity2.3 M $-91.0%

Cash & ST Investments42.1 M $-35.5%

Total Debt1.5 M $+6.0%

Net Debt-40.6 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
ATNM	5.89	65.9%	1.79	5.1%
RTALB	1.21	1.2%	0.90	84.9%
MSB	—	—	—	—
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
ATNM	5.89	65.9%	1.79	5.1%
SGMO	0.70	-102.0%	0.07	-31.6%
OTLK	0.54	-93.8%	-0.31	-132.4%
PDSB	2.26	407.5%	0.21	15.8%
PMVP	11.14	0.3%	1.19	91.1%
VRCA	2.02	9.0%	1.69	41.4%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-22.9 M $—

Capital Expenditures106 K $—

Free Cash Flow-23 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
ATNM	-25,417.8%	-25,535.6%	117.8%	97.5%
RTALB	58.5%	88.6%	10.8%	42.9%
MSB	-87.7%	-90.0%	2.3%	76.1%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
ATNM	-25,417.8%	-25,535.6%	117.8%	97.5%
SGMO	-261.4%	-261.8%	0.3%	73.3%
OTLK	-14,121.8%	-14,121.8%	0.0%	77.2%
PDSB	—	—	—	13,162.3%
PMVP	—	—	—	95.7%
VRCA	-38.0%	-38.0%	0.0%	79.2%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on ATNM

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.